Squamous cell carcinoma
☆ Liphethong tsa 2022 Stiftung Warentest tse tsoang Jeremane, khotsofalo ea bareki ka ModelDerm e ne e le tlase hanyane ho feta lipuisano tse lefelloang tsa telemedicine.
Squamous cell carcinoma well differentiated ― Keratosis ya actinic e bapileng le yona e a hlokomelwa.
References
Squamous cell carcinoma (SCC) ke mofetše oa bobeli o atileng haholo oa letlalo United States, kamora basal cell carcinoma. Hangata e qala ka maqeba a precancerous a bitsoang actinic keratosis , 'me a ka hasana likarolong tse ling tsa' mele. Sesosa se seholo ke ho pepesehela mahlaseli a ultraviolet (UV) a tsoang letsatsing, a bokellanang ha nako e ntse e ea. Kalafo hangata e kenyelletsa ho tlosoa ha opereishene, haholo-holo bakeng sa SCC hloohong le molaleng. Kalafo ea radiation ke khetho bakeng sa bakuli ba tsofetseng kapa ba sa khoneng ho buuoa. Immunosuppression e eketsa kotsi ea SCC. Le hoja e sa tloaeleha, SCC e ka ata, haholo-holo ho bakuli ba nang le mekhoa ea ho itšireletsa mafung e fokolang. Ho hlahlojoa khafetsa le ho sireletsa letsatsi ho bohlokoa ho ba nang le SCC.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Cutaneous squamous cell carcinoma (CSCC) ke mofetše oa bobeli o atileng ho batho, 'me lipalo tsa ona lia nyoloha. Le hoja CSCC hangata e bontša boitšoaro bo botle ba kliniki, e ka hasana sebakeng sa heno le likarolong tse ling tsa 'mele. Bo-rasaense ba hlokometse litsela tse itseng tse amehang ntlafatsong ea CSCC, e lebisang ho phekolo e ncha. Palo e phahameng ea liphetoho le kotsi e eketsehileng ho bakuli ba nang le immunosuppressed e bakile nts'etsopele ea immunotherapy. Tlhahlobo ena e sheba metso ea liphatsa tsa lefutso ea CSCC le liphekolo tsa morao-rao tse lebisang limolek'hule tse itseng le tsamaiso ea 'mele ea ho itšireletsa mafung.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
○ Tlhahlobo le Kalafo
#Dermoscopy
#Skin biopsy